Sign In
Buy SAVA
$1.96
+0 (+0%)
At Close: Jun 03, 2026
Why Cassava Sciences Stock Investors Are Pulling Back
10:49am, Friday, 27'th Aug 2021
The neurodegenerative diseases-focused biopharma Cassava Sciences, Inc. (NASDAQ: SAVA) has now lost half of its market capitalization. What Happened: Cassava shares plunged Wednesday in reaction to
Which Biotech Stock Will Shock the Market in 2022?
10:40am, Friday, 27'th Aug 2021
Over the last few years, three tiny biotechs emerged out of nowhere to give amazing returns to early investors. Which biotech might pull off a similar feat in 2022?
Quanterix Corp. QTRX, -9.21% said that while it was previously engaged by Cassava Sciences Inc. SAVA, -12.38% to perform sample testing, the digitized biomarker analysis company said it, or its employ
Specious Claims And Spurious Accusations Are All The Bears Can Muster Against Cassava Sciences
08:44am, Friday, 27'th Aug 2021
The petition filed against Cassava Sciences is so misleading and wrong-headed it seems an intentional act of FUD and not a serious request.
After A 30% Fall Cassava Stock Is Likely To See Lower Levels
08:30am, Friday, 27'th Aug 2021
The stock price of Cassava Sciences, a clinical stage biotechnology company focused on treatment for Alzheimer's disease, has seen a large 31% decline in a single trading session on Aug 25. SAVA stock
NEW YORK--(BUSINESS WIRE)--Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Cassava Sciences, Inc. (“Cassava Sciences” or
Cassava Shareholder Alert
05:59pm, Thursday, 26'th Aug 2021
Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Cassava To Contact Him Directly To Discuss Their OptionsNew York, New York--(Newsfile Co
SAVA Alert: Berman Tabacco Investigates Cassava Sciences, Inc. for Potential Securities Claims in Connection with FDA Citizen Petition
02:10pm, Thursday, 26'th Aug 2021
Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) - Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc.
LOS ANGELES--(BUSINESS WIRE)---- $SAVA #SAVA--INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Cassava Sciences, Inc.
Cassava Sciences Likely To Survive Latest Attack On Alzheimer's Drug, But Caveat Emptor
01:07pm, Thursday, 26'th Aug 2021
Cassava has received the go-ahead from the FDA to initiate two pivotal trials of its Alzheimer's therapy Simufilam. One week ago, however, a citizen's petition filed with the FDA insisted that data fr
Why Traders Shouldn't Bargain Hunt in Cassava Stock
12:43pm, Thursday, 26'th Aug 2021
Wall Street is notorious for its overreactions, but when it comes to SAVA stock's cratering, investors consider other historical precedents. The post Why Traders Shouldn't Bargain Hunt in Cassava Stoc
NEW YORK--(BUSINESS WIRE)--WHY: Rosen Law Firm, a global investor rights law firm, announces it is investigating potential securities claims on behalf of shareholders of Cassava Sciences, Inc. (NASDAQ
As Allegations Swirl, Can Investors Still Count on Cassava Sciences Stock?
11:01am, Thursday, 26'th Aug 2021
This once-promising biotech is now struggling to stay afloat.
SAN FRANCISCO, Aug. 26, 2021 /PRNewswire/ -- Hagens Berman urges Cassava Sciences, Inc. (NASDAQ: SAVA) investors with significant losses to submit your losses now. Visit: www.hbsslaw.com/inv
Biotech Stock Tries to Recover as Alzheimer's Drug Draws Questions
09:29am, Thursday, 26'th Aug 2021
Cassava Sciences Inc (NASDAQ:SAVA) is up 4.1% at $84.16 this morning, in an attempt to bounce back from yesterday's news that its Alzheimer's drug was facing scrutiny.
